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Abstract 
Optically active 1,5-benzothiazepines belong to the well known benzothiazepine type substances. 
Some of them possess important bioactivities. In this review article, optically active 2,3-dihydro-
1,5-benzothiazepin-4(5H)-ones, their 3-amino and 3-hydroxy derivatives, comprising the most 
important groups of these benzothiazepines, will be discussed in detail. Less known optically 
active 1,5-benzothiazepines will also be included.  
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1. Introduction 
 
The 1,5-benzothiazepine is one of the three possible benzocondensed derivatives, viz. 1,4-, 4,1- 
and 1,5-benzothiazepines of the 1,4-thiazepine.1 The parent 1,5-benzothiazepine has not yet been 
published in the chemical literature, but its derivatives are the most frequently investigated 
benzothiazepine type compounds. 2,3-Dihydro-1,5-benzothiazepin-4(5H)-ones are especially 
popular substances since they possess wide range of bioactivities. Therefore, the 1,5-
benzothiazepines are useful compounds in the drug research which has stimulated the invention 
of a wide range of synthetic methods for their preparation and chemical transformations. This is 
due for the synthesis of optically active 1,5-benzothiazepines as well.     
 The major aim of this review is to provide examples for the synthesis of the known groups of 
the optically active 1,5-benzothiazepines. In some cases, the stereochemical studies of the 
synthesized new compounds are included. Their most important bioactivities will also be 
discussed together with the synthesis of special groups of substances. 
 
 
2. Synthesis and Stereochemistry of Optically Active 2,3-Dihydro-1,5-
benzothiazepin-4(5H)-ones Substituted at Position 2  
 
The first representatives of the optically active 1,5-benzothiazepines were the enantiomers of the 
2-(carboxymethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (3). Racemic 3 was prepared by 
the heating of a mixture of 2-aminothiophenol (1) and glutaconic acid (2). Resolution of this 
racemate with brucine provided the (+)-3 and (-)-3 enantiomers2 (Scheme 1). Since this work 
was published as early as 1927, absolute configuration data are not mentioned in this paper. This 
was the sole example for the preparation of optically active benzothiazepines for four decades. 
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Scheme 1. (a) heating at 120-130 oC for 20 min; (b) brucine, dilute HCl.2 
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 The next communication was the optical resolution of the 2,3-dihydro-5-[2-
(dimethylamino)ethyl]-2-phenyl-1,5-benzothiazepin-4(5H)-one (thiazesim) with (+)-tartaric acid 
in 1968.3 A common feature of these two examples is that 1,5-benzothiazepines with a functional 
group capable of salt formation were synthesized as racemates. Optical resolution of these 
racemates provided the appropriate optically active 1,5-benzothiazepine enantiomers. 
 For the synthesis of optically active 2,3-dihydro-1,5-benzothiazepin-4(5H)-ones substituted 
at position 2 a retrosynthetic approach was invented by Lévai et al.4 This retrosynthetic approach 
enabled the first synthesis of optically active 2,3-dihydro-1,5-benzothiazepin-4(5H)-ones without 
functional groups capable of salt formation. Racemic nitrocarboxylic acids 4 and 55 were used as 
starting materials. Brucine salts of compounds 4 and 5 were crystallized from ethanol until each 
salt showed constant optical rotation, then the diastereomeric salts were decomposed with dilute 
hydrochloric acid to afford optically active nitrocarboxylic acid enantiomers. Optically active 
nitrocarboxylic acids were reduced to the appropriate aminocarboxylic acids 6 and 7 on 
treatment with Zn powder in acetic acid. Optically active 2,3-dihydro-1,5-benzothiazepin-4(5H)-
ones 8 and 9 were obtained by the ring closure of the optically active aminocarboxylic acids 6 
and 7 in boiling xylene4 (Scheme 2). 
 Conformation of the seven-membered ring was determined by NMR spectroscopy.6 Absolute 
configuration of the centre of chirality of these optically active 2,3-dihydro-1,5-benzothiazepin-
4(5H)-ones (8,9) and their optically active intermediates were elucidated by a combined 
utilization of X-ray diffraction analysis and circular dichroism (CD) spectroscopic 
measurements.7,8 
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Scheme 2. (a) brucine, HCl; (b) Zn powder, MeCOOH; (c) boiling xylene.4 
  
 2,3-Dihydro-1,5-benzothiazepin-4(5H)-ones substituted at position 2 can also be prepared by 
the ring enlargements of 1-thiochromanones.9 Either the Schmidt reaction of 1-
thiochromanones10 or the Beckmann rearrangement of their oximes11 can be  utilized for this 
purpose. Dike et al. synthesized (R)-2,3-dihydro-2-methyl-1,5-benzothiazepin-4(5H)-one [(R)-8] 
by the Beckmann rearrangement of the (R)-2-methyl-1-thiochromanone [(R)-10]12 and (R)-2,3-
dihydro-2-phenyl-1,5-benzothiazepin-4(5H)-one [(R)-9] also by the Beckmann rearrangement 
(R)-2-phenyl-1-thiochromanone [(R)-11]13 (Scheme 3). N-Alkylation of compound (R)-9 with 2-
(dimethylamino)ethyl chloride provided (R)-thiazesim [(R)-12] which was the first optically 
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active 1,5-benzothiazepine with known bioactivity since it was found to exhibit central nervous 
system activity.3,13   
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Scheme 3. (a) PPA, 120 oC, 2 h; (b) Cl(CH2)2N(Me)2.12,13 
 
 (R)-2,3-Dihydro-2,5-dimethyl-1,5-benzothiazepin-4(5H)-one [(R)-15] was prepared by the 
reaction of (S)-β-butyrolactone (14) and o-(N-methylamino)thiophenol (13) without isolation of 
the appropriate carboxylic acid intermediate (Scheme 4).14 However, this procedure has not 
hitherto been utilized for the synthesis of related optically active 2,3-dihydro-1,5-benzothiazepin-
4(5H)-ones. 
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Scheme 4. (a)iPrOH, NaH, 20 min; (b) DCC, CH2Cl2, 20 oC.14  
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3. Synthesis of Optically Active 3-Alkyl-2,3-dihydro-1,5-benzothiazepin-
4(5H)-ones 
 
The first representative of optically active 3-alkyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-ones 
was synthesized by Ohno et al.15,16 2-Aminothiophenol (1) was allowed to react with diethyl 
benzylidenemalonate (16) to obtain aminocarboxylic acid derivative 17 ring closure of which 
afforded 2,3-dihydro-3-(ethoxycarbonyl)-2-phenyl-1,5-benzothiazepin-4(5H)-one (18).  
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Scheme 5. (a) iPrOH; (b) Et3N.HCl, 180 ºC, 3 h; (c) LiAlH4; (d) SOCl2, pyridine, benzene;  
(e) N-methylpiperazine.15,16 
 
 Compound 18 was then converted into 3-hydroxymethyl derivative 19 on reduction with 
LiAlH4. The hydroxy group was replaced by a chlorine atom and compound 20 was obtained 
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which was reacted with N-methylpiperazine to yield a cis/trans mixture of 2,3-dihydro-3-[(4-
methylpiperazinyl)methyl]-2-phenyl-1,5-benzothiazepin-4(5H)-one (21) (Scheme 5). The 
diastereomers were then separated and the cis-21 was optically resolved with tartaric acid to 
afford (-)-cis-2,3-dihydro-3-[(4-methylpiperazinyl)methyl]-2-phenyl-1,5-benzothiazepin-4(5H)-
one as an optically pure substance. Its hydrochloride (BTM-1086) showed antiulcer and gastric 
secretary effects.16,17 It is worth mentioning that no data are available concerning the elucidation 
of the stereochemistry of 1,5-benzothiazepines 18-21. 
 
 
4. Synthesis and Bioactivities of Optically Active 3-Amino-2,3-dihydro-1,5-
benzothiazepin-4(5H)-ones  
 
Optically active 3-amino-2,3-dihydro-1,5-benzothiazepin-4-(5H)-ones are especially useful 
substances in the drug research. One of their important effects is the angiotensin converting 
enzyme (ACE) inhibitory activity. The angiotensin converting enzyme (ACE) is a dipeptidyl 
carboxypeptidase catalyzing the hydrolysis of the decapeptide angiotensin I to the octapeptide 
angiotensin II. This octapeptide is a known vasoconstrictor promoting the release of the 
aldosterone. As a result, the ACE raises the blood pressure and, therefore, several ACE inhibitors 
are used to treat the hypertension and congestive heart failure.18 For this reason, a wide variety of 
ACE inhibitors have been synthesized and tested. In this review, we discuss only the optically 
active 3-amino-2,3-dihydro-1,5-benzothiazepine type ACE inhibitors. 
 The first representative of the optically active 3-amino-2,3-dihydro-1,5-benzothiazepin-
4(5H)-ones was synthesized by Slade et al.19 Source of the chirality was the L-cysteine as a 
natural amino acid used as building block. o-Fluoronitrobenzene (22) was reacted with N-acetyl-
L-cysteine (23) to afford nitrocarboxylic acid 24 subsequent deacetylation of which gave (S)-(o-
nitrophenyl)-L-cysteine (25). Compound 25 was reacted with benzyl chloroformate to obtain (S)-
(o-nitrophenyl)-N-(carbobenzyloxy)-L-cysteine (26) reduction of which provided (S)-(o-
aminophenyl)-N-(carbobenzyloxy)-L-cysteine (27). Ring closure of 27 yielded 3(R)-
[(carbobenzyloxy)amino]-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (28). Deprotection of the 
amino group gave the target 3(R)-amino-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (29) 
(Scheme 6).19  
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Scheme 6. (a) NaHCO3, EtOH; (b) H2SO4, H2O; (c) benzyl chloroformate, NaOH, H2O; (d) 
NH4Cl, MeOH, Zn dust; (e) DMF, carbodiimide; (f) HBr, AcOH.19 
 
 The 3(R)-[(carbobenzyloxy)amino]-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (28) was 
further functionalized to afford ACE inhibitor  1,5-benzothiazepine derivatives 30 and 31 (Figure 
1).20-22 
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Figure 1. New ACE inhibitors.20-22  
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 Amblard et al.23,24 synthesized 3(S)-amino-2,3-dihydro-1,5-benzothiazepin-4(5H)-ones (36) 
similarly to the reaction  sequence described for the synthesis of the 3(R)-amino-2,3-dihydro-1,5-
benzothiazepin-4(5H)-one (29)19 using D-cysteine instead of L-cysteine as the source of 
chirality. o-Fluoronitrobenzenes 32 were allowed to react with Boc-D-cysteine (33) to afford 
nitrocarboxylic acid derivatives 34 which yielded aminocarboxylic acids 35 on reduction with Zn 
dust.  Ring closure of compounds 35 gave 3(S)-[(carbobenzyloxy)amino]-2,3-dihydro-1,5-
benzothiazepin-4(H)-ones 36. Alkylation of 36 with ethyl bromoacetate gave 5-
[(ethyoxycarbonyl)methyl]-1,5-benzothiazepines 37. Saponification of these ethyl esters 
provided the target carboxylic acids 38 (Scheme 7).23 
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Scheme 7. (a) NaHCO3, EtOH, H2O; (b) NH4Cl, MeOH, Zn dust; (c) NaHCO3, BOP, DMF;  
(d) BrCH2COOEt, KOH, n-Bu4NBr, THF; (e) NaOH, EtOH.23 
 
 Robl et al.25,26 synthesized optically active 3(R)-amino-2,3-dihydro-1,5-benzothiazepin-
4(5H)-ones 40 and 41 starting from 3(R)-amino-2,3-dihydro-5-[(ethoxycarbonyl)methyl]-2,3-
dihydro-1,5-benzothiazepin-4(5H)-one (39) as outlined in Scheme 8. Compounds 40 and 41 
were found to possess high in vitro and in vivo inhibitory activity against ACE and neutral 
endopeptidase (NEP).  
 Human leukocyte elastase (HLE) inhibitor 3(R)-amino-2,3-dihydro-1,5-benzothiazepin-
4(5H)-one derivative 43 was synthesized by Skiles et al.27 starting from 3(R)-amino-5-
(carboxymethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one (42) (Scheme 9). 
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Scheme 8. (a) acylation; (b) NaOH, EtOH.25,26 
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Scheme 9. (a) amine, CDI, THF.27 
 
 Kawanishi et al.28 synthesized a wide variety of 3(S)-amino-2,3-dihydro-1,5-benzothiazepin-
4(5H)-ones 45 and 46 starting from 2,3-dihydro-3(S)-phthalimido-1,5-benzothiazepin-4(5H)-one 
(44) (Scheme 10). 
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Scheme 10. (a) deprotection, isocyanate; (b) alkylation.28 
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 Solid-phase synthesis of optically active 3-amino-2,3-dihydro-1,5-benzothiazepin-4(5H)-
ones, using cysteine derivatives as building blocks, has also been described in the literature.29 
 Amblard et al.30-33 synthesized bradykinin agonist optically active 3-amino-2,3-dihydro-1,5-
benzothiazepin-4(5H)-ones. Some representatives of such benzothiazepines (cf. 47 and 48) are 
shown in Figure 2. 
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Figure 2. Examples of bradykinin agonist benzothiazepines.30-33 
 
 
5. Synthesis and Bioactivities of Optically Active 2,3-Dihydro-3-hydroxy-1,5-
benzothiazepin-4(5H)-ones 
 
Kugita et al.34-36 published the first synthesis of 2-aryl-2,3-dihydro-3-hydroxy-1,5-
benzothiazepin-4(5H)-ones in 1970. 2-Nitrothiophenol (49) was reacted with phenylglycidic 
esters 50 to afford the appropriate nitrocarboxylic acid esters 51 which were reduced to 
aminocarboxylic acid esters 52. Compounds 52 were saponified to obtain the free carboxylic 
acids 53 ring closure of which provided the target 2-aryl-2,3-dihydro-3-hydroxy-1,5-
benzothiazepin-4(5H)-ones 54 as diastereomeric mixtures (Scheme 11). As a result of further 
developments, depending on the reaction conditions of the ring opening of the phenylglycidic 
esters, either cis- or trans-2-aryl-2,3-dihydro-3-hydroxy-1,5-benzothiazepin-4(H)-ones were 
obtained as single diastereomers.  
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Scheme 11. (a) NaHCO3, EtOH; (b) FeSO4.H2O, EtOH; (c) NaOH, EtOH; (d) xylene, reflux.34 
 
 It has been proven that numerous derivatives of the 2-aryl-2,3-dihydro-3-hydroxy-1,5-
benzothiazepin-4(5H)-ones are useful seven-membered heterocyclic compounds in the drug 
research. Their N-alkylated and 3-O-acylated derivatives 55 and 56 were synthesized and tested 
in the early stage of the research of these benzothiazepines.36-43 Some general chemical 
transformations providing such benzothiazepines are illustrated in Scheme 12.  
 Among benzothiazepines shown in Scheme 12, the 3-acetoxy-2,3-dihydro-5-[2-
(dimethylamino)ethyl]-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one (diltiazem) was 
found to be an especially active substance with its coronary vasodilatory,38-40 antiarrythmic41 and 
haemodynamic42 effects. The diltiazem can exist in four diastereomeric forms. Its has also turned 
out that the (+)-diltiazem, viz. the 3(S)-acetoxy-2,3-dihydro-5-[2-(dimethylamino)-ethyl]-2(S)-(4-
methoxyphenyl)-1,5-benzothiazepin-4(5H)-one is the most effective isomer. Its effectiveness 
stimulated the efforts to develop various synthetic protocols for its preparation. These efforts 
were further supported by the fact that nowadays only optically pure active ingredients are 
allowed to use for the production and sale of medicines. Owing to the huge amount of 
literaterature data, in this paragraph we included only the most adequate selected examples to 
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illustrate some procedures used for this purpose which means that not all papers published on 
this topic are included and discussed. 
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Scheme 12. (a) ClCH2CH2NMe2, dioxane, NaH; (b) pyridine, AcCl.36 
  
 The first synthesis of (+)-diltiazem was achieved by Inoue et al.44 in 1973 and its (2S,3S) 
absolute configuration was determined by X-ray diffraction analysis. Diastereomeric salt 
formation of cis-3-(2-aminophenylthio)-2-hydroxy-3-(4-methoxyphenyl)propionic acid (57) with 
various optically active amines followed by the liberation of the optically active aminocarboxylic 
acids (2S,3S)-57 and (2R,3R)-57. Ring closure of these optically active intermediates provided 
the optically active benzothiazepines (2S,3S)-58 and (2R,3R)-58. Further chemical 
transformations of the 58 yielded the target (+)- and (-)-diltiazem 59 (Scheme 13). 
 A wide variety of synthetic procedures based on the preparation of optically active 
carboxylic acid intermediates have been worked out. Selected examples of these procedures are 
included in this paragraph. The key starting materials of the synthesis are the 3-phenylglycidates. 
Utilization of optically active 3-phenylglycidates have been published by several research 
groups.45-48 Racemic nitrocarboxylic acid49 or aminocarboxylic acid50 intermediates were 
optically resolved via distereomeric salt formation. Optically active intermediates used for the 
synthesis of the diltiazem have also been prepared by enzyme-catalyzed resolution.51-54 In some 
cases, either the aminocarboxylic acid intermediates or the racemic 1,5-benzothiazepine 
derivatives were optically resolved to yield the optically active target compounds.55 
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Scheme 13. (a) optically active amine, HCl; (b) xylene, reflux; (c) ClCH2CH2NMe2, dioxane, 
NaH; (d) pyridine, AcCl.44 
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 Optically active methyl (2R,3S)-3-(4-methoxyphenyl)glycidate [(-)-61] was obtained by the 
transesterification of (-)-(2R,3S)-3-(4-methoxyphenyl)glycidic acid 4-chloro-3-(methylphenyl) 
ester [(-)-60] obtained by the optical resolution of (±)-60 by preferred crystallization in DMF.56 
 Chemical transformations of compound (-)-61 outlined in Scheme 14 provided (+)-diltiazem 
[(+)-59]. Methyl (2R,3S)-3-(4-methoxyphenyl)glycidate   [(-)-61] has also been prepared starting 
from 4-methoxyacetophenone via dynamic kinetic resolution.57 In special cases, optically active 
aminocarboxylic amides were used as intermediates for the preparation of (+)-diltiazem.58,59  
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Scheme 14. (a) MeOH, NaOMe; (b) 2-aminothiophenol; (c) chlorobenzene, methanesulfonic 
acid, reflux for 1 h; (d) ClCH2CH2NMe2, dioxane, NaH, pyridine, AcCl.57 
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 Starting from the appropriate optically active aminocarboxylic acid esters 62 and 63 (2S,3S)- 
and (2R,3R)-isomers of the 2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-
4(5H)-one (58) were prepared60 (Scheme 15). 
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Scheme 15. (a) p-TSA, xylene, reflux, 3 h.60 
 
 Microwave-assisted synthesis of cis- and trans-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-
1,5-benzothiazepin-4(5H)-one (58) has also been described61 in the literature. However, this 
publication is the sole example for the utilization of this technique.  
 Asymmetric reduction of 2-(4-methoxyphenyl)-1,5-benzothiazepin-3,4-(2H,5H)-dione (64) 
with NaBH4 in combination with optically active α-amino acids gave 2,3-dihydro-3(S)-hydroxy-
2(S)-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one (58) (Scheme 16).62  
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Scheme 16. (a) NaBH4, L-proline.62 
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 Optical purity, conformation and absolute configuration of these optically active 1,5-
benzothiazepines and their optically active intermediates have been elucidated by NMR 
spectroscopic measurements, X-ray diffraction analysis and circular dichroism (CD) 
spectroscopy.49,63-66  
 Several metabolites of the diltiazem have been prepared and were found to possess various 
bioactivities.43,67-73 Biological and pharmacological activities of these benzothiazepines have 
been studied in numerous research laboratories and pharmaceutical companies. Their most 
important effects are antihypertensive, cardiovascular, spasmolytic, calcium channel blocking 
and antithrombotic activities. On all these bases, the 2,3-dihydro-3-hydroxy-1,5-benzothiazepin-
4(5H)-oes are the most valuable benzothiazepine type compounds in the drug research.  
 
 
6. Miscellaneous 
 
In this closing paragraph, a few interesting representatives of the optically active 1,5-
benzothiazepines are included. In special cases, optically active 1,5-benzothiazepines were 
synthesized by the reaction of optically active natural products or their semisynthetic derivatives 
with 2-aminothiophenol (1). Tronchet and Gentile74 reacted the α,β-unsaturated ketone 65 
derived from sugar with 2-aminothiophenol (1) to obtain a spirobenzothiazepine type compound 
66 (Scheme 17). In the case of this optically active 1,5-benzothiazepine, the source of the 
chirality was the sugar used as building block.  
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Scheme 17. (a) MeOH, MgSO4, 60 ºC, 24 h.74  
 
 Mushfiq et al.75-77 synthesized optically active 1,5-benzothiazepines condensed with a steroid 
skeleton. Steroid derivatives 67 bearing an α,β-unsaturated ketone unit were allowed to react 
with 2-aminothiophenol (1) to afford the benzothiazepine derivatives 68 (Scheme 18). In these 
cases, the source of the chirality was the steroid building block. 
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Scheme 18. (a) MeOH, ccHCl.76  
 
 
7. Conclusions 
 
Chemistry of well known groups of optically active 1,5-benzothiazepines are summarized in this 
review article. The most important procedures used for their synthesis are discussed with the 
help of adequate examples. Their most valuable bioactivities are mentioned in brief. Selected 
original papers included in the References will help the reader to find the original information 
concerning a special 1,5-benzothiazepine derivative. 
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